#USA #Berwyn #Nordic Pharma #LACRIFILL #Dry Eye

Nordic Pharma's Innovative Cannula Launch

In a notable advancement for ocular health, Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., recently announced the addition of cannulas to their offerings for LACRIFILL® Canalicular Gel. This innovation, aimed at improving the treatment of dry eye symptoms, comes at a time when the organization celebrated a major milestone of treating over 100,000 patients within just two years of the product's introduction.

Dr. Eric Donnenfeld, MD, Chairman of OCLI Vision and NYU Langone Health, commended the LACRIFILL® product, highlighting its effectiveness in managing the ocular surface and enhancing patient comfort during eye procedures. He described it not merely as a temporary solution but as a pivotal approach to ocular surface care. Dr. Mile Brujic, OD from Premier Vision Group, echoed similar sentiments, noting the gel's role in significantly improving both the visual outcomes and comfort for patients suffering from chronic dry eye.

Improved Accessibility for Providers

The integration of cannulas with the pre-filled syringes of LACRIFILL® is designed to streamline the administration process for healthcare providers. Each syringe contains sufficient gel for both upper and lower canaliculi in each eye, making it easy for practitioners to help their patients. The addition of these cannulas marks an acknowledgment of feedback received from the optometric and ophthalmic community, indicating a focused response to improve ease of use.

This direct approach not only enhances provider convenience but also underscores the commitment of Nordic Pharma to addressing patient needs effectively and efficiently. With studies indicating that approximately 6.8% of American adults experience dry eye syndrome, the LACRIFILL® initiative represents a pivotal shift toward more interventionist strategies in ophthalmology.

Doctor Testimonials

Many healthcare professionals have lauded the efficacy of LACRIFILL®. The feedback from practitioners who have utilized the product has been overwhelmingly positive, emphasizing the importance of managing conditions related to the ocular surface as integral to modern eye care. The clinical evidence supporting its use further bolsters its reputation as a game-changer in daily operations within eye practices.

Educational Initiatives

To demonstrate the product's application effectively, Nordic Pharma is set to hold live demonstrations at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting. These sessions aim to showcase how the gel can be utilized for improved patient care, offering professionals an opportunity to witness its benefits firsthand.

Conclusion

With its ongoing commitment to innovation and patient-centered healthcare solutions, Nordic Pharma, Inc. is setting a new standard in the management of dry eye symptoms. The inclusion of cannulas in its LACRIFILL® shipments is just one example of how the company is listening to healthcare providers and enhancing their treatment capabilities. As they continue to reach significant milestones in patient care and product availability, the future looks promising for both Nordic Pharma and the patients relying on their products to alleviate dry eye discomfort.

For more detailed information about LACRIFILL® and its applications, you can visit their official website at lacrifill.com.